Zika virus (ZIKV) is present in urine, saliva, tears, and breast milk, but the transmission risk 22 associated with these body fluids is currently unknown. We evaluated the risk of ZIKV 23 transmission through mucosal contact in rhesus macaques. Application of high-dose ZIKV 24 directly to the tonsils of 3 rhesus macaques resulted in detectable plasma viremia in all animals 25 by 2 days post-exposure; virus replication kinetics were similar to those observed in animals 26 infected subcutaneously. Three additional macaques inoculated subcutaneously with ZIKV 27 served as saliva donors to assess the transmission risk from contact with oral secretions from 28 an infected individual. Seven naive animals repeatedly exposed to donor saliva via the 29 conjunctivae, tonsils, or nostrils did not become infected. Our results suggest that there is a risk 30 of ZIKV transmission via the mucosal route, but that the risk posed by oral secretions from 31 individuals with a typical course of ZIKV infection is low. 32 33
from animal 511690 ( Fig. 2c) . We were only able to collect saliva directly on two occasions from 87 animal 664817, and both samples were negative for ZIKV RNA (data not shown). ZIKV RNA 88 was detected in saliva from animal 590870 on days 6-9 post infection and from animal 511690 89 on days 8 and 10 post infection (Fig. 3) . Overall, when saliva samples were available, ZIKV 90 RNA was detected more consistently and at more time points than in oral swabs (Fig. 3) . By 14 91 dpi, ZIKV RNA was undetectable in the tested body fluids of all animals infected by tonsil 92 inoculation. 93
Sera from macaques that were infected by application of ZIKV to the tonsils neutralized ZIKV-94 FP across a range of serum dilutions. Indeed, neutralization curves prepared using sera from all 95 3 animals revealed a similar profile as compared to sera from animals infected subcutaneously 96 (see Supplementary Figure 1 ). All animals developed neutralizing antibodies (nAb) with a 90% 97 plaque reduction neutralization test (PRNT 90 ) titer of 1:160 (664817 and 511690) or 1:80 98 (590870) by 28 dpi. Together, these results show that application of high doses of ZIKV to the 99 oral mucosae can result in systemic infection and induce humoral immune responses in a 100 manner similar to subcutaneous infection. 101
Inoculation with oral secretions from ZIKV-infected donors does not result in systemic 102
infection. The highest concentration of ZIKV RNA we observed in the oral secretions of infected 6 donors daily from 3-10 dpi (cohorts 1 and 3) or 3-12 dpi (cohort 2) and applied to the tonsils, 111 nostrils, or conjunctivae of 1 or more recipients (See Fig. 1 for details) . This 3-10 or 3-12 dpi 112 timeframe encompassed the period of time in which ZIKV RNA was detected in non-blood body 113 fluids of animals infected subcutaneously in our previous studies. All saliva donors had 114 detectable ZIKV plasma viremia by 1 dpi, peaking 3-5 dpi, (range = 7.35 x 10 5 -5.42 x 10 6 115 vRNA copies/mL) and resolving by 14 dpi (Fig. 2a ). ZIKV RNA was detected in the passively 116 collected urine of all 3 donors. Peak urine viral loads were detected 7-10 dpi (range = 2.68 x 10 4 117 -1.95 x 10 5 vRNA copies/mL) ( Fig. 2b) . 118
We monitored ZIKV RNA in saliva over time through collection of oral swabs and, whenever 119 possible, saliva, from donor animals, to measure vRNA in the inocula used to challenge the 120 recipients ( Fig. 2c and Fig. 3 ). We detected ZIKV RNA in the oral swab eluate of two saliva 121 donors (448436 and 861138); levels peaked at 2.77 x 10 3 vRNA copies/mL at 7 dpi and 1.18 x 122 10 4 vRNA copies/mL at 10 dpi respectively. The last saliva donor (756591) did not have 123 detectable ZIKV RNA in oral swab samples. We were unable to consistently collect saliva from 124 448436, but ZIKV RNA in the saliva of the 861138 was detectable 4-14 dpi and peaked at 1.12 125
x 10 4 vRNA copies/mL ( Fig. 3 ). 756591 had detectable ZIKV RNA in saliva that peaked at 2.32 x 126
Infectivity of saliva from subcutaneously infected donors to IFNAR -/-mice. Because no 135
recipients of saliva from infected donors had detectable systemic ZIKV infections, we tested the 136 infectivity of donor saliva in IFNAR-/-mice. These mice are highly susceptible to ZIKV 137 infection 23,24 , even at challenge doses as low as 1 x 10 2 fluorescent focus units 23 (approximately 138 1 x 10 2 PFU (personal communication Michael Diamond)). We inoculated 5-to 6-week-old 139 IFNAR-/-mice with ZIKV RNA-positive macaque saliva from 861138 collected at 10 dpi (1.12 x 140 10 4 vRNA copies/mL; 50 μl inoculum; ~1 x 10 -0.25 PFU (estimated from 1:1000 ratio of 141 PFU:vRNA copies/mL of ZIKV stock 21,22 )) or oral swab eluate from 448436 collected at 7 dpi 142 (2.77 x 10 3 vRNA copies/mL; 50 μl inoculum; ~1 x 10 -0.86 PFU (estimated)), and monitored them 143 for 25 days for weight loss and mortality. All control and experimental mice survived with no 144 evidence of morbidity ( Supplementary Fig. 2 ). Furthermore, ZIKV RNA was undetectable in 145 mouse serum at 3 dpi (the approximate peak of viremia in mice infected previously 23, 24 ) and the 146 animals did not seroconvert by 25 dpi, as assessed by PRNT (data not shown). These data 147 suggest that saliva from ZIKV-infected macaques did not contain enough replication-competent 148 virus to initiate infection in these sensitive hosts. The same saliva and oral swab samples were 149 concurrently inoculated onto Vero cells to attempt to quantify the infectious dose the mice might 150 have received; however, both the saliva and oral swab sample used for the mouse challenge 151 experiments gave no plaques on these cells. Our plaque assay and mouse inoculation doses 152 contained on the order of 100-500 vRNA copies, while our previous studies suggest that the 153 ratio of vRNA copies to plaque-forming units is approximately 1000:1, further supporting the 154 conclusion that very little infectious virus was present in these samples 21, 22 . Together these 155 results suggest that macaques with ZIKV virus loads in the usual range after subcutaneous 156 infection shed very small quantities of infectious ZIKV in saliva.
Discussion

159
Humans and animals infected with ZIKV are known to shed virus (or vRNA) in multiple body 160 fluids, including blood, urine, saliva, and genital secretions 21,25-27 . Sexual transmission of ZIKV 161 between humans has been documented in several cases, but the risk of transmission from more 162 casual contact has been difficult to evaluate. Human-to-human transmission via non-sexual 163 contact has been reported in a single case to date, though this case involved a source patient 164 with extremely high viremia; in this case contact with tears or sweat from the source patient was 165 hypothesized to be the mode of transmission 20 . Here we used a nonhuman primate model to 166 investigate whether exposure to ZIKV via mucous membranes, particularly the oropharyngeal 167 mucosa, represents an infection risk. 168
Application of a high dose (8 x 10 5 PFU) of Asian-lineage ZIKV to the palatine tonsils resulted in 169 systemic infection in 3 of 3 rhesus macaques, suggesting that productive infection can indeed 170 be initiated at the oropharyngeal mucosa. The kinetics and magnitude of ZIKV replication in 171 plasma in these three animals were similar to those observed in animals infected 172 subcutaneously with the same stock of ZIKV-FP ( Fig. 2a ), and all 3 animals developed strong 173 nAb titers against homologous ZIKV-FP by 28 dpi. Detection of ZIKV RNA in oral swabs, saliva, 174 and urine was variable in the animals that received a direct tonsil challenge, findings that were 175 also similar to those from animals infected subcutaneously in this and a previous study 21 . 176
Limitations associated with sample collection could have influenced our ability to detect vRNA in 177 fluids other than blood. For example, time from urination to sample collection varied because 178 urine was collected passively from pans in the animals' housing. Similarly, there is wide 179 variation in the degree to which individual animals salivate while under sedation. As a result, it 180 was not always possible to collect saliva from each animal at each time point. Oral swabs provided a more consistent means for collecting oral secretions, but as the relatively small 182 amount of secretions absorbed by the swabs must be eluted in medium, detection of ZIKV RNA 183 or infectivity may not be as sensitive in swab sample as in undiluted saliva. Accordingly, ZIKV 184
RNA was more consistently detected in the saliva versus oral swabs when both sample types 185 were available ( Fig. 3 ). Although ZIKV RNA was detectable in the saliva of ZIKV donor animals 186 861138 and 756591 and in oral swab samples from 861138 and 448436, transfer of saliva from 187 donors to the mucosae of naive recipients did not result in ZIKV transmission. In addition, donor 188 saliva produced no detectable plaques on Vero cells. Moreover, IFNAR-/-mice inoculated with 189 saliva or oral swab samples from infected donor macaques showed no overt signs of disease 190 and did not seroconvert. Our previous studies suggest that the proportion of vRNA copies to 191 infectious particles from both virus stock and sera from infected animals is approximately 192 1000:1 21,22 . The highest viral load that we detected in a saliva sample in this study was only 1.1 193
x 10 4 vRNA copies/mL; given that we were never able to collect a full 1mL of saliva, it seems 194 likely that saliva transferred to recipients (tonsil maximum of 100-200μL, conjunctivae maximum 195 of 50μL, and nasal passage maximum of 100μL) in our study likely contained less than three 196
infectious ZIKV virions. 197
In addition to sample collection limitations, saliva may represent a natural barrier to virus 198 transmission in the oral cavity. A number of different viruses, such as HIV and influenza A, are 199 detected in the saliva of infected individuals, but mucosal infection in many cases is considered 200 low risk 28-30 . This may be due in part to the antimicrobial constituents present in saliva, which 201 include mucins, lysozyme, peroxidase, defensins, and salivary agglutinin 30 . However, even with 202 these natural barriers to infection, challenge of animals with a higher dose of ZIKV directly to the 203 tonsils resulted in productive infection. A bolus challenge of SIV directly to the oral cavity has 204 also been shown to infect rhesus macaques 31 . The authors of that study suggested that their 205 oral bolus transmission model might approximate HIV transmission through oral-genital 206 contact 31 . The finding that an oral bolus of virus may overcome natural mucosal barriers to 207 infection is especially interesting because ZIKV has been detected in semen for many months 208 following acute infection and at viral loads significantly higher than those detected in blood 209 plasma (8.6 log 10 copies/mL) 32, 33 . ZIKV RNA and infectious virus have also been detected in 210 breast milk, another potential route of oral mucosal exposure 34 . The potential for transmission of 211
HIV through breast milk is well documented in humans and is associated with the milk viral load 212 35,36 . Although there have been no documented cases of transmission between a nursing mother 213 and her infant, a ZIKV viral load of greater than 8 x 10 6 vRNA copies/mL has been reported in 214 the breast milk in a woman with acute ZIKV infection 18 . 215
Taken together, our results suggest that there is a risk of ZIKV transmission via the oral 216 mucosal route, as shown by systemic infection in 3 of 3 macaques after application of high-dose 217 infectious virus to the tonsils. However, the actual risk of transmission via mucosal exposure to 218 saliva may be low-saliva from donor animals with typical plasma viremia harbored little or no 219 infectious virus and could not mediate transmission of ZIKV in our study. However, it must be 220 noted that secretions, including saliva from individuals with unusually high viral load, semen, 221 and breast milk, could pose a transmission risk. Vero cells (African green monkey kidney cells; CCL-81). The virus stock used in this study was 252 prepared by inoculation onto a confluent monolayer of C6/36 mosquito cells (Aedes albopictus 253 larval cells; CRL-1660). Cell lines were obtained from American Type Culture Collection 254 (ATCC), were not further authenticated, and were not specifically tested for mycoplasma. A 255 single, clarified harvest of virus, with a titer of 5.9 x 10 6 PFU/mL (3.9 x 10 9 vRNA copies/mL) 256
ZIKV-FP was used as stock for all subcutaneous inoculations. 257
Tonsil challenges. The ZIKV-FP stock was thawed, diluted in PBS to 1 x 10 6 PFU/mL, and 258 maintained on ice until inoculation. Each animal was anesthetized and 8 x 10 5 PFU ZIKV-FP 259 was applied directly to the palatine tonsils (maximum of 400μL per tonsil) via pipet after 260 visualization with a laryngoscope. Animals were closely monitored by veterinary and animal care 261 staff for adverse reactions and signs of disease. Animals were examined, and blood, urine, oral 262 swabs, and saliva were collected from each animal daily from 1 through up to 12 dpi and then 263 weekly thereafter through 28 dpi. 264 Subcutaneous inoculations. The ZIKV-FP stock was thawed, diluted in PBS to 1 x 10 4 265 PFU/mL, and loaded into a 3mL syringe maintained on ice until inoculation. For subcutaneous 266 inoculations, each of three Indian-origin rhesus macaques was anesthetized and inoculated 267 subcutaneously over the cranial dorsum with 1mL virus stock containing 1 x 10 4 PFU. All 268 animals were closely monitored by veterinary and animal care staff for adverse reactions and 269 signs of disease. Animals were examined, and blood, urine, oral swabs, and saliva were 270 collected from each animal daily from 1 through up to 12 dpi and then weekly thereafter through 271 28 dpi. were closely monitored by veterinary and animal care staff for adverse reactions and signs of 287 disease. As described previously, animals were examined, and blood, urine, saliva, and oral 288 swabs were collected from each animal daily during challenge and then weekly thereafter 289 through 28 days after final challenge. 290
Plaque reduction neutralization test (PRNT). Macaque serum samples were screened for 291
ZIKV neutralizing antibody utilizing a plaque reduction neutralization test (PRNT) on Vero cells 292 (ATCC #CCL-81). Endpoint titrations of reactive sera, using a 90% cut off (PRNT 90 ), were 293 performed as described in 37 against ZIKV-FP. Neutralization curves were generated using 294
GraphPad Prism software. The resulting data were analyzed by non-linear regression to 295 estimate the dilution of serum required to inhibit 50% of infection.
Live virus isolation.
Mice deficient in the alpha/beta interferon receptor on the C57BL/6 297 background (IFNAR-/-) were bred in the pathogen-free animal facilities of the University of 298
Wisconsin-Madison School of Veterinary Medicine. Four groups (n=12) of 5-to 6-week-old, 299 mixed sex mice were used to test infectivity of ZIKV RNA in macaque saliva. Mice were 300 inoculated in the left, hind foot pad with 50μL of saliva or saliva swab eluate in viral transport 301 media (VTM) from samples that tested positive for ZIKV RNA by qRT-PCR. Mock-infected 302 experimental control mice received saliva or saliva swab eluate in VTM collected from ZIKV-303 negative control macaques. Following inoculation, mice were monitored twice daily for the 304 duration of the study. Sub-mandibular blood draws were performed and serum was collected to 305 verify viremia via qRT-PCR and nAb titers via PRNT. 306 Viral RNA isolation. Plasma was isolated from EDTA-anticoagulated whole blood collected the 307 same day by Ficoll density centrifugation at 1860 rcf for 30 minutes. Plasma was removed to a 308 clean 15mL conical tube and centrifuged at 670 rcf for an additional 8 minutes to remove 309 residual cells. Urine was opportunistically collected from a pan beneath each animal's cage and 310 centrifuged at 500 rcf for 5 minutes to remove cells and debris. Saliva was collected via pipet 311 from under the tongue or using sterile oral swabs run under the tongue while animals were 312 anesthetized. Saliva collected via pipet was used to directly inoculate recipient animals in 313 cohorts 2 and 3. Additional saliva, when available, was removed from the collection pipet, 314 centrifuged at 500 rcf for 5 minutes, and added to 650μL viral transport media at a ratio of no 315 more than one part saliva to three parts viral transport media. Swabs were placed in viral 316 transport media for 60-90 minutes, then vortexed vigorously and centrifuged at 500 rcf for 5 317 minutes to elute saliva. Prior to extraction, oral swab eluates were pelleted by centrifugation at shown. All points not distinguishable above the limit of quantification (100 vRNA copies/mL) are Only time points in these four animals at which both saliva (gray) and oral swabs (black) were tested simultaneously are shown. All points not distinguishable above the limit of quantification (100 vRNA copies/mL) are present on the x-axis.
